Hydroxyurea attenuates activated neutrophil-mediated sickle erythrocyte membrane phosphatidylserine exposure and adhesion to pulmonary vascular endothelium

Am J Physiol Heart Circ Physiol. 2008 Jan;294(1):H379-85. doi: 10.1152/ajpheart.01068.2007. Epub 2007 Nov 9.

Abstract

Activated neutrophils increase erythrocyte phosphatidylserine (PS) exposure. PS-exposed sickle red blood cells (SSRBCs) are more adhesive to vascular endothelium than non-PS-exposed cells. An increase in SSRBC fetal hemoglobin (HbF) concentration has been associated with improved rheology and decreased numbers of vasoocclusive episodes. This study examined the effects of HbF, PS-exposed SSRBCs, and chronic hydroxyurea (HU) treatment on activated neutrophil-mediated SSRBC retention/adherence in isolated-perfused rat lungs. Lungs were perfused with erythrocyte suspensions from 1) individuals homozygous for hemoglobin S with 0-7% HbF (SS), 2) with > or =8% HbF (SS + F), and 3) individuals homozygous for hemoglobin S treated with HU therapy for > or =1 yr (SS + HU). Retention of SSRBCs from the SS + HU group was significantly less than that seen in both the SS and SS + F groups. No difference was observed between the SS and SS + F groups. The percentage of HbF and F-cells did not differ between the SS + F and SS + HU groups. At baseline, the proportion of PS-exposed SSRBCs was not different between the SS and SS + HU groups. However, SSRBC treatment with activated neutrophil supernatant caused a twofold increase in PS-exposed SSRBCs in the SS control and no change in the SS + HU group. We conclude that 1) HU attenuates SSRBC retention/adherence in the pulmonary circulation seen in response neutrophil activation, 2) HU stabilizes SSRBC membrane PS, and 3) HU attenuation SSRBC retention/adherence in the pulmonary circulation occurs through a mechanism(s) independent of HbF.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anemia, Sickle Cell / blood
  • Anemia, Sickle Cell / drug therapy*
  • Anemia, Sickle Cell / genetics
  • Animals
  • Antisickling Agents / pharmacology*
  • Antisickling Agents / therapeutic use
  • Cell Adhesion / drug effects*
  • Endothelium, Vascular / drug effects*
  • Endothelium, Vascular / metabolism
  • Erythrocyte Membrane / drug effects*
  • Erythrocyte Membrane / metabolism
  • Fetal Hemoglobin / metabolism
  • Hemoglobin, Sickle / genetics
  • Hemoglobin, Sickle / metabolism
  • Homozygote
  • Humans
  • Hydroxyurea / pharmacology*
  • Hydroxyurea / therapeutic use
  • In Vitro Techniques
  • Inflammation Mediators / metabolism
  • Lung / blood supply*
  • Male
  • Neutrophil Activation*
  • Neutrophils / metabolism*
  • Perfusion
  • Phosphatidylserines / metabolism*
  • Rats
  • Rats, Sprague-Dawley
  • Time Factors

Substances

  • Antisickling Agents
  • Hemoglobin, Sickle
  • Inflammation Mediators
  • Phosphatidylserines
  • Fetal Hemoglobin
  • Hydroxyurea